Cargando…

Antiphospholipidantikörpersyndrom

□ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Rüdiger, Scheuermann, Ernst-Heinrich, Viertel, Achim, Geiger, Helmut, Scharrer, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Urban & Vogel 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095803/
https://www.ncbi.nlm.nih.gov/pubmed/10194954
http://dx.doi.org/10.1007/BF03044707
_version_ 1783510688972406784
author Schmidt, Rüdiger
Scheuermann, Ernst-Heinrich
Viertel, Achim
Geiger, Helmut
Scharrer, Inge
author_facet Schmidt, Rüdiger
Scheuermann, Ernst-Heinrich
Viertel, Achim
Geiger, Helmut
Scharrer, Inge
author_sort Schmidt, Rüdiger
collection PubMed
description □ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses, repeated fetal losses and thrombocytopenia. Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions (secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune disorders, infectious diseases, neoplastic disorders, in association with the use of certain drugs or in otherwise healthy individuals (primary antiphospholipid antibody syndrome, PAPS). □ TREATMENT: Patients with thrombosis associated with APA should receive long-term anticoagulation therapy, whereas treatment of asymptomatic patients seems to be not indicated, because only approximately 10% of patients with APA may develop thrombotic complications. In patients with PAPS there is no evidence that the prophylactic administration of immunosuppressive drugs will prevent thromboembolic events.
format Online
Article
Text
id pubmed-7095803
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Urban & Vogel
record_format MEDLINE/PubMed
spelling pubmed-70958032020-03-26 Antiphospholipidantikörpersyndrom Schmidt, Rüdiger Scheuermann, Ernst-Heinrich Viertel, Achim Geiger, Helmut Scharrer, Inge Med Klin (Munich) Übersicht □ BACKGROUND: Antiphospholipid antibodies comprise a family of auto-antibodies mainly characterized by the presence of the lupus anticoagulant (LA) and anticardiolipin antibodies (ACA). □ CLINICAL APPEARANCE: The antiphospholipid antibody syndrome is defined by the appearance of frequent thromboses, repeated fetal losses and thrombocytopenia. Other clinical manifestations associated with APA include migraine, chorea, hemolytic anemia, heart valve disease, Budd-Chiari syndrome, perpetual pancreatitic episodes, intestinal infarctions, malignant hypertension, livedo reticularis, pre-eclampsia, fetal growth retardation or catastrophic antiphospholipid syndrome. LA and ACA occur in a variety of clinical conditions (secondary antiphospholipid antibody syndrome, SAPS), including other autoimmune disorders, infectious diseases, neoplastic disorders, in association with the use of certain drugs or in otherwise healthy individuals (primary antiphospholipid antibody syndrome, PAPS). □ TREATMENT: Patients with thrombosis associated with APA should receive long-term anticoagulation therapy, whereas treatment of asymptomatic patients seems to be not indicated, because only approximately 10% of patients with APA may develop thrombotic complications. In patients with PAPS there is no evidence that the prophylactic administration of immunosuppressive drugs will prevent thromboembolic events. Urban & Vogel 1999 /pmc/articles/PMC7095803/ /pubmed/10194954 http://dx.doi.org/10.1007/BF03044707 Text en © Urban & Vogel 1999 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Übersicht
Schmidt, Rüdiger
Scheuermann, Ernst-Heinrich
Viertel, Achim
Geiger, Helmut
Scharrer, Inge
Antiphospholipidantikörpersyndrom
title Antiphospholipidantikörpersyndrom
title_full Antiphospholipidantikörpersyndrom
title_fullStr Antiphospholipidantikörpersyndrom
title_full_unstemmed Antiphospholipidantikörpersyndrom
title_short Antiphospholipidantikörpersyndrom
title_sort antiphospholipidantikörpersyndrom
topic Übersicht
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095803/
https://www.ncbi.nlm.nih.gov/pubmed/10194954
http://dx.doi.org/10.1007/BF03044707
work_keys_str_mv AT schmidtrudiger antiphospholipidantikorpersyndrom
AT scheuermannernstheinrich antiphospholipidantikorpersyndrom
AT viertelachim antiphospholipidantikorpersyndrom
AT geigerhelmut antiphospholipidantikorpersyndrom
AT scharreringe antiphospholipidantikorpersyndrom